Oncology Central

Predicting the chance of relapse after tamoxifen treatment in breast cancer

0

Breast cancer treatment emerged as the model for tailored therapy with the introduction of antihormonal modalities and the measurement of estrogen receptors as a clinically applicable biomarker [1]. In the adjuvant setting tamoxifen treatment is administered to reduce the risk of recurrence and death in estrogen receptor (ER)-positive breast cancer [2]. It has been confirmed by multiple clinical trials that ER-negative tumors almost entirely fail to respond to antihormonal agents [3,4]

To view restricted content, please:
Share:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.